Overview

Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate of efficacy and safety of HCP1904-3 and RLD2001-1 alone in patients with essential hypertension inadequately controlled on RLD2001-1 monotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Hanmi Pharmaceutical Company Limited